3Koizumi W,Narahara H, Hara T, et al. S-l plus cisplatinversus S-l alone for first-line treatment of advanced gastriccancer(SPIR ITS trial) : a phase HI trial [J]. Lancet Oncol,2008,9(3):215-221.
6Makt-Manino M,Malnino R. Clinical studies of three oral pro-drug of 5-fluorouracil (capecitabine, UFT. S-l) : a review[J].Oncologist,2002,7(4) : 288-323.
7Sano T, Aiko T. New Japanese classifications and treatmentguidelines for gastric cancer: revision concepts and majorrevised points[J]. Gastric Cancer, 2011,14(2) : 97-100.
4Kelesen D, Van de Velde C, Minsky B. Gastric cancer: clinical management. In: Kelsen D, Daly JM, Kern SE, et al. Gastroin-tes- tinal oneology [ M ] . Philadelphia: PA Lippincott Williams & Wilkins,2002. 408-416.
5Vanhoefer U, Rougier P, Wilke H, et al. Final results of a random- ized phase Ⅲ trial of sequential high-dose metbotrexate,fluoroum- cil, and doxorubicin versus etoposide, leucovorin, and fluorouracil and eisplatin in advanced gastric caneer;A trial of the European Organization for Research and Treatment of Gastrointestinal Tract Cancer Cooperative Group [ J ]. J Clin Oneol, 2000, 18 : 2648- 2657.
6Makt-Manino M, Malnino R. Clinical studies of three oral prodrug of 5-fluorouracil ( capecitabine, UFT, S-I ) : a review [ J ]. Oncologist ,2002,7 (4) :288-323.
7Tanaka F, Fukuse T, wada H, et al. The history, mechanism and clinical use of oral 5-fluorouracil derivative chemotherapeutic a- gents [ J ]. Curr Pharm Biotechnol,2000,1 (2) : 137-164.
8Shirasaka T, Shimamato Y, Ohshimo H, et al. Development of a novelfonn of an oral 5-fluorouracil derivative( S-1 )directed to the potentiation of the tumor selective cytotoxicity of 5-fl uorouracil by two biochemical modulators[ J ]. Anticancer Drugs, 1996,7 ( 5 ) : 548-557.
9Shirasaka T, Tsukuda M, lnuyama Y, et al. New oral anti-cancer drug,Ts-1 (S-1)-form bench to clinic[ J]. Gall To Kagaku Ryo- ho,2001,28 (6) :855-864.
10Mizoshita T, Kataoka H, Kubota E, et al. Gastric phenotype sig- net-ring cell carcinoma of the stomach with multiple bone metas- tases effectively treated with sequential methotrexate and 5-flu- orouracil [ J ]. Int J Clin Oncol,2008,13 (4) : 373 - 376.
